Transcriptional signature of TP53 biallelic inactivation identifies a group of multiple myeloma patients without this genetic condition but with dismal outcome.

"CONFLICT OF INTEREST Maria‐Victoria Mateos receives honoraria and speakers' bureau compensation from Janssen and Celgene, Onyx, Takeda, Novartis, and Bristol‐Myers Squibb, unconnected with the submitted work. Norma C. Gutiérrez receives honoraria from Janssen that are unconnected with the work presented here. All the other authors declare no competing financial interests."

"This work has been supported by grants from the Instituto de Salud Carlos III (ISCIII) co‐funded by European Union FEDER funds (projects PI16/01074 and PI19/00674), the Asociación Española Contra el Cáncer (grant PROYE20047GUTI) and the Gerencia Regional de Salud, Junta de Castilla y León (grants GRS 2058/A/19 and GRS 2331/A/21). Cristina De Ramón, Elizabeta A. Rojas and Ignacio J. Cardona‐Benavides have been supported by the Asociación Española Contra el Cáncer (CLJUN18010DERA), the Consejería de Educación de Castilla y León and the Instituto de Salud Carlos III (PFIS‐2020: FI20/00226), respectively. The authors thank the MMRF for access to the CoMMpass dataset. The authors would also like to thank Phil Mason for his help in reviewing the English language of the manuscript."